colitis inflammatory bowel disease (IBD)
Conditions
Interventions
Patients will be randomized to either two weeks daily 20 mg Prednisone and
Calcium vit. D prior to surveillance colonoscopy or no treatment at all.
Patients in the treatment arm will be asked to fil
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients diagnosed with either ulcerative colitis or Crohn???s disease by established criteria scheduled for surveillance colonoscopy between April 1, 2008 and March 31, 2009 in the Erasmus Medical Center will be entered into this study.
Exclusion criteria
Exclusion criteria: Exclusion criteria are: diabetes, pregnancy, hypertension and known adverse reactions on earlier use of Prednisone.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary study outcome is presence of histological inflammation of the mucosa | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study paramteres are presence of other pathologic findings during endoscopy and/or in the pathology report and the management of these pathological findings. Patient characteristics that will furthermore be used in the analysis are demographic factors, like age and sex and disease characteristics like disease duration, activity and course as well as medication use. | — |
Countries
Netherlands
Outcome results
None listed